Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
about
Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology GuidelineRandomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.Less than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points.An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girlsAdolescent Participation in HPV Vaccine Clinical Trials: Are Parents Willing?Primary Immunization of Human Papillomavirus Vaccine in the Pediatric Population: What Is the Verdict Now?No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model.Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females.Factors that Predict Parental Willingness to Have Their Children Vaccinated against HPV in a Country with Low HPV Vaccination Coverage.Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia
P2860
Q26749285-7532EA77-8FC4-4F4C-B2E1-699482F167B0Q37118381-9E3C90FB-BECB-44CA-AF55-18353708CB19Q37135074-64A57ADE-A709-477B-BD42-48BF4BBDE566Q37135276-76A67AEE-8BD3-410E-AE1A-2C9AC942D0B4Q38742564-B306F79F-1C66-4663-9AB4-77CCBF3ABB99Q39306396-9EBF8511-BEDE-4D5C-A7A3-797DB70DBD67Q39447985-74A4CD48-276A-43FE-8A6B-82EB70A3E201Q40129472-53E497E8-182D-48B1-A72E-62A16C71AA23Q40168801-CBC20763-786F-4A76-8A78-A402217CE1CDQ47549756-3F9EDCF2-375E-448F-887C-B23324BA712BQ50788444-4E0177BA-AAF5-447D-9FDA-F3DF59FE7391Q52609699-446AA34F-638A-4FCE-A2BA-C278B3922A5DQ55540751-AAE4AB87-80B0-4616-8D01-D03B337F4A93
P2860
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Comparative immunogenicity and ...... th 12 from a randomized trial.
@ast
Comparative immunogenicity and ...... th 12 from a randomized trial.
@en
type
label
Comparative immunogenicity and ...... th 12 from a randomized trial.
@ast
Comparative immunogenicity and ...... th 12 from a randomized trial.
@en
prefLabel
Comparative immunogenicity and ...... th 12 from a randomized trial.
@ast
Comparative immunogenicity and ...... th 12 from a randomized trial.
@en
P2093
P2860
P50
P1476
Comparative immunogenicity and ...... th 12 from a randomized trial.
@en
P2093
Anthony Pak-Yin Liu
Bee Wah Lee
Benoit De Muynck
Damien Friel
Florence Thomas
Fong Seng Lim
Franck Thollot
Helen May Lin Oh
Lars Rombo
Marjan Hezareh
P2860
P304
P356
10.1080/21645515.2015.1050570
P577
2015-07-01T00:00:00Z